UniSA uses cookies to remember your preferences, analyse traffic, track usage patterns, and personalise content. In some instances, UniSA shares personal information collected by cookies with UniSA's third party service providers and Adelaide University (as UniSA's future successor). See our privacy notification for further details. To adjust your cookie settings, click 'More information'. By clicking 'Accept and continue', you consent to our use of cookies.
Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 1000 citations, with an h-index of 17 and an i22 index of 20.
Currently, Abid is working as an Academic Research Associate leading projects comprising active targeting of cardiovascular disease and tumor via ligand-conjugated Lipid Nanoparticles encapsulating mRNA/siRNA and ligand-conjugated polymeric NPs.
Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 1000 citations, with an... Read more
About me
Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 1000 citations, with an h-index of 17 and an i10 index of 22.
Currently, Abid is working as an Academic Research Associate leading projects comprising active targeting of cardiovascular disease and tumor via ligand-conjugated Lipid Nanoparticles encapsulating mRNA/siRNA and ligand-conjugated polymeric NPs.
About me
Doctor of Philosophy Shanghai Jiao Tong University
Doctor of Pharmacy Gomal University
Master of Philosophy University of Malakand
Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 1000 citations, with an h-index of 18 and an i10 index of 23.
Currently, Abid is working as an Academic Research Associate leading projects comprising active targeting of cardiovascular disease and tumor via ligand-conjugated Lipid Nanoparticles encapsulating mRNA/siRNA and ligand-conjugated polymeric NPs.
Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 1000 citations, with an... Read more
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2024 |
Open access
2
2
|
2023 |
14
14
20
|
2022 |
1
|
2022 |
Open access
59
59
3
|
2022 |
76
63
3
|
Year | Output |
---|---|
2022 |
1
|
2022 |
5
|
2022 |
7
|
Year | Output |
---|---|
2024 |
Open access
2
2
|
2023 |
7
7
4
|
2023 |
14
14
20
|
2022 |
Open access
59
59
3
|
2022 |
76
63
3
|
Research
Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 1000 citations, with an h-index of 17 and an i10 index of 22.
Currently, Abid is working as an Academic Research Associate leading projects comprising active targeting of cardiovascular disease and tumor via ligand-conjugated Lipid Nanoparticles encapsulating mRNA/siRNA and ligand-conjugated polymeric NPs.
External engagement & recognition
Organisation | Country |
---|---|
Abasyn University | PAKISTAN |
Affiliated Hospital of Nantong University | CHINA |
Aix-Marseille University | FRANCE |
Beijing Institute of Microbiology and Epidemiology | CHINA |
Beijing Institute of Technology | CHINA |
Capital University of Science and Technology | PAKISTAN |
China Pharmaceutical University | CHINA |
Chinese Academy of Sciences | CHINA |
Chinese PLA General Hospital | CHINA |
Guangxi Medical University | CHINA |
Guangzhou Medical University | CHINA |
Hebei University | CHINA |
Henan Normal University | CHINA |
Jiangnan University | CHINA |
Jiangsu University | CHINA |
Nankai University | CHINA |
Nantong University | CHINA |
National Center for Nanoscience and Technology of China | CHINA |
Nestlives Private Limited | INDIA |
Peking University | CHINA |
Quaid-i-Azam University | PAKISTAN |
Shandong University | CHINA |
Shanghai Jiao Tong University | CHINA |
Shanghai University | CHINA |
Shanghai Veterinary Research Institute | CHINA |
Shantou University | CHINA |
Shantou University Medical College | CHINA |
Shaqra University | SAUDI ARABIA |
Shenzhen University | CHINA |
Soochow University | CHINA |
Tianjin Medical University | CHINA |
Tianjin University | CHINA |
University of California | UNITED STATES |
University of Macau | MACAU (SAR OF CHINA) |
University of Malakand | PAKISTAN |
University of Texas Southwestern Medical Center | UNITED STATES |
Women's and Children's Hospital | AUSTRALIA |
Yangzhou University | CHINA |
Yantai University | CHINA |
Zhejiang University | CHINA |
Zhengzhou University | CHINA |